The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia

Απλή σελίδα τεκμηρίου
dc.contributor.authorNakou, E. S.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorKiortsis, D. N.en
dc.contributor.authorDerdemezis, C. S.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T16:50:32Z
dc.date.available2015-11-24T16:50:32Z
dc.identifier.issn1465-6566-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9617
dc.rightsDefault Licence-
dc.subjectcholesterolen
dc.subjectezetimibeen
dc.subjecthigh-density lipoproteinen
dc.subjectlipoprotein associated phospholipase a(2)en
dc.subjectorlistaten
dc.subjectparaoxonaseen
dc.subjectsubclassesen
dc.subjecttriglyceridesen
dc.subjectactivating-factor-acetylhydrolaseen
dc.subjectcardiovascular risk-factorsen
dc.subjectcoronary-heart-diseaseen
dc.subjectintervention trialen
dc.subjectphospholipase a(2)en
dc.subjectmetabolic syndromeen
dc.subjectcholesterolen
dc.subjectsubfractionsen
dc.subjectparaoxonaseen
dc.subjectldlen
dc.titleThe effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemiaen
heal.abstractBackground: High-density lipoprotein (HDL) includes discrete subfractions. HDL exhibits anti-atherogenic properties, which have been partly linked to the activity of HDL-associated enzymes, such as the lipoprotein associated phospholipase A(2) (HDL-LpPLA(2)) and paraoxonase-1 (PON1). Objective: We assessed in an open-label randomised study the effect of orlistat and ezetimibe, alone or in combination, on plasma HDL subclasses and HDL-associated enzyme activities in overweight and obese subjects (body mass index > 28 kgm(2)) with hypercholesterolemia [total cholesterol > 200 mg/100 ml (5.2 mmol/l)]. Methods: Eighty-six people were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg, three times daily (O group), ezetimibe 10 mg/day (E group) or both (OE group) for 6 months. HDL subfractions were determined using a polyacrylamide gel-tube electrophoresis method. Results: Levels of HDL cholesterol (HDL-C) and apolipoprotein Al did not change significantly in any group. In group O the cholesterol concentration of HDL-2 subclass increased significantly, while the cholesterol of HDL-3 subclass decreased significantly. In groups E and OE HDL-2 subclass did not significantly change, while the cholesterol concentration of HDL-3 subclass decreased significantly. We observed a non-significant decrease in the HDL-LpPLA(2) and POW activity in all groups. However, the ratios of both enzyme activities to low-density lipoprotein cholesterol (LDL-C) levels (an index of atherogenicity) significantly increased in all groups. Conclusion: Although HDL-C levels did not change after treatment with orlistat and ezetimibe, alone or in combination, there were alterations of the HDL-2 and HDL-3 subclasses. The activity of HDL-LpPLA(2) and POW per mg LDL-C increased significantly in all groups.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDoi 10.1517/14656560802548430-
heal.identifier.secondary<Go to ISI>://000262018400003-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1517/14656560802548430-
heal.journalNameExpert Opinion on Pharmacotherapyen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ